DarwinHealth Publication Reports Step-by-Step Protocol for its Tumor Checkpoint-Based, Compound-to-Clinic (C2C) Cancer Drug Discovery Pipeline: Elucidates a Patient-to-Model-to-Patient (PMP) Roadmap for Precision- and Mechanism-Based Identification and Clinical Validation of Novel, Investigational and FDA-Approved Therapeutic Agents Targeting Tumor Regulatory Architecture
By asianet
DarwinHealth, Inc., (www.DarwinHealth.com) a New York-based biotechnology and cancer drug discovery company announces the September 9, 2022 online publication in Current Protocols (Wiley Science) of their proprietary cancer drug discovery and validation pipeline, “A Patient-to-Model-to-Patient (PMP) cancer drug and biomarker discovery protocol for identifying and validating therapeutic agents targeting tumor regulatory architecture.” Logo – https://mma.prnewswire.com/media/966600/DarwinHealth_Logo.jpg … Continued